J&J investment could be a tipping point for microbiome research

06/6/2013 | Forbes

Johnson & Johnson and Second Genome announced plans to collaborate on developing drugs that work on diseases such as ulcerative colitis by modifying intestinal bacteria. Second Genome, co-founded by former Pfizer innovation center president Corey Goodman, uses DNA sequencing to analyze organisms in a human stool sample, and then uses proprietary software to determine how drugs would affect the microbes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR